Enterisol Salmonella T/C® Vaccine Reduces the Clinical Impact and Colonization of Monophasic Salmonella enterica Serovar I 4,[5], 12:i:-

Fernando Leite; Paulo Arruda; Dianna Jordan; S. Bearson

Zoonotic Agents

Enterisol Salmonella T/C® Vaccine Reduces the Clinical Impact and Colonization of Monophasic Salmonella enterica Serovar I 4,[5], 12:i:-

Authors: Fernando Leite (Boehringer Ingelheim Animal Health USA Inc.) , Paulo Arruda (VRI-AMVC) , Dianna Jordan (Boehringer Ingelheim Animal Health USA Inc.) , S. Bearson (U.S. Department of Agriculture, Agricultural Research Service)

Abstract

The monophasic Salmonella I 4,[5],12:i:- serovar is now the most common Salmonella serovar identified in U.S. swine clinical cases. This serovar has also become one of the most common to cause human foodborne salmonellosis and is also the most frequent multidrug resistant (MDR; resistance to ≥ 3 antimicrobial classes) serovar in the U.S. Given the significance of this serotype to both swine health and food safety, the objective of our study was to evaluate the impact of the Enterisol Salmonella T/C® vaccine on reducing clinical parameters as well as colonization of swine with MDR Salmonella I 4,[5],12:i:-.

Keywords:

How to Cite: Leite, F. , Arruda, P. , Jordan, D. & Bearson, S. (2023) “Enterisol Salmonella T/C® Vaccine Reduces the Clinical Impact and Colonization of Monophasic Salmonella enterica Serovar I 4,[5], 12:i:-”, SafePork. 14(1).